AtriCure (ATRC) has put fresh numbers on the table for Q2 2026, reporting revenue of US$153.6 million and basic EPS of US$0.18, alongside net income of US$9.0 million. These results come as the trailing twelve months show EPS of US$0.22 on revenue of US$569.6 million and net income of US$10.6 million. Over the past six quarters, the company has seen quarterly revenue move from US$123.6 million in Q1 2025 to US$153.6 million in Q2 2026, while basic EPS has shifted from a loss of US$0.14 to a profit of US$0.18. This sets up a story that now centers on how much of this earnings turn is reflected in AtriCure's margins and operating discipline.

See our full analysis for AtriCure.

With the headline figures in place, the next step is to see how these margins and growth rates line up with the most common narratives around AtriCure, and where the latest earnings print challenges those views.

Profitability Turn Shows Up in TTM Numbers

• On a trailing twelve month basis, AtriCure has moved from a loss of US$38.2 million in Q1 2025 to a profit of US$10.6 million in Q2 2026, with TTM basic EPS shifting from a loss of US$0.81 to a profit of US$0.22 over the same window.
• Consensus narrative points to operating leverage from product adoption and international growth, and that view lines up with the move in TTM net income from a loss of US$28.8 million in Q3 2025 to a profit of US$10.6 million in Q2 2026. Over that period, revenue rose more gradually from US$518.3 million to US$569.6 million, which means the profitability turn is leaning heavily on margins rather than a sudden revenue surge.
  • This combination of a modest TTM revenue step up of about US$51.3 million against a swing of roughly US$39.3 million in TTM net income heavily supports the idea that operating leverage has been a key driver in the recent results.
  • At the same time, the relatively steady revenue path compared with the much sharper move in earnings is a reminder that any reversal in cost discipline or pricing power could have an outsized impact on future profitability.

Fast EPS Recovery Versus Gradual Revenue Trend

• Quarterly basic EPS has moved from a loss of US$0.14 in Q1 2025 to a profit of US$0.18 in Q2 2026, while quarterly revenue over the same span rose from US$123.6 million to US$153.6 million.
• Bulls argue that expanding procedure volumes and higher value devices can support strong earnings growth, and the shift from a quarterly net loss of US$6.7 million in Q1 2025 to net income of US$9.0 million in Q2 2026, against a revenue change of about US$30.0 million, fits with that view but also raises the question of how repeatable this level of margin progress is if revenue growth slows.
  • The bullish narrative looks for durable margin expansion, and the move from small losses like the US$0.3 million net loss in Q3 2025 to US$8.9 million of net income in Q2 2026 shows how sensitive the bottom line has been to incremental revenue and cost control.
  • However, with quarterly revenue stepping up in smaller increments, such as from US$134.3 million in Q3 2025 to US$140.5 million in Q4 2025 and then US$141.2 million in Q1 2026, the pace of earnings improvement may depend heavily on maintaining tight spending and pricing, not just top line momentum.

For readers who want to see how bullish investors connect these margin shifts to the long term story around procedures, pricing, and product launches, 🐂 AtriCure Bull Case

Valuation Gaps: P/S, DCF Fair Value and Price Targets

• AtriCure trades at a P/S of 3.1x versus a peer average of 7.3x and a US Medical Equipment industry average of 2.8x, while a DCF fair value of US$0.74 sits far below the current share price of US$35.04 and a consensus analyst price target of US$47.00.
• Bears highlight that high expected earnings growth can still leave a stock exposed if valuation support is weak, and the combination of a DCF fair value at US$0.74 alongside a consensus target of US$47.00 and a current price of US$35.04 underlines how different models and assumptions can point in very different directions, even as the company shifts from a TTM net loss of US$36.4 million in Q2 2025 to a TTM profit of US$10.6 million in Q2 2026.
  • This wide spread between DCF fair value and both the market price and analyst target challenges the idea that earnings growth alone is enough to make the bearish valuation concerns fade away.
  • At the same time, the move in TTM basic EPS from a loss of US$0.77 in Q2 2025 to a profit of US$0.22 in Q2 2026 gives bears a data point to monitor, because any slowdown in that improvement could matter more when the valuation signals are already pulling in different directions.

Skeptical readers who want to understand how cautious investors frame these valuation tensions around AtriCure can walk through the detailed bear case via 🐻 AtriCure Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AtriCure on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of improving profitability and valuation debate around AtriCure leaves you on the fence, take a closer look at the underlying data now and pressure test your own thesis using the 3 key rewards and 1 important warning sign.

See What Else Is Out There

AtriCure's earnings turnaround still sits against a backdrop of valuation tension, with a very low DCF fair value compared to its current share price and analyst targets.

If that kind of valuation gap makes you cautious, it is worth looking at companies where pricing looks more aligned with fundamentals through the 49 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.